22 research outputs found
Culprit plaque characteristics in younger versus older patients with acute coronary syndromes: An optical coherence tomography study from the FORMIDABLE registry
Objectives: Culprit plaque characteristics in young patients who
experience an Acute Coronary Syndrome (ACS) evaluated by OCT (Optical
Coherence Tomography) have to be defined. The OCT-FORMIDABLE is a
multicentre retrospective registry enrolling consecutive patients with
ACS who performed OCT in 9 European centres.
Methods: Patients were divided in two groups according to age at
presentation: juvenile-ACS (age <= 50 years) and not juvenile-ACS (age >
50 years). Primary end-point was the prevalence of plaque rupture (PR).
Secondary end point was the prevalence of thin cap fibro atheroma
(TCFA), fibrocalcific and fibrotic plaque.
Results: 285 patients were included, 71 (24.9%) in juvenile-ACS group
and 215 (75.1%) in not juvenile-ACS group. Younger patients showed a
trend for a higher prevalence of TCFA (70 vs. 58%, P = 0.06) and
thrombus presence (62 vs. 51%, P = 0.1), while no statistical
difference concerning PR (70 vs. 64%, P = 0.29). Of interest patients
younger that 35 years showed a higher prevalence of PR compared to
patients aged between 35 and 45 or 45 and 50 years (100 vs. 72 vs. 55%,
P = 0.03). Culprit plaque in juvenile-ACS group showed more frequently a
reduced mean cap thickness (119 +/- 66 vs. 155 +/- 95 nm, P = 0.05) and
less frequently fibrotic (32 vs. 57%, P < 0.001) or fibrocalcific (17
vs. 36%, P = 0.003) characteristics.
Conclusions:young patients with ACS show a trend for a higher prevalence
of culprit PR, a thinner cap and less fibrotic or fibrocalcific
components
Cell Therapy for Refractory Angina: A Reappraisal
Cardiac cell-based therapy has emerged as a novel therapeutic option for patients dealing with untreatable refractory angina (RA). However, after more than a decade of controlled studies, no definitive consensus has been reached regarding clinical efficacy. Although positive results in terms of surrogate endpoints have been suggested by early and phase II clinical studies as well as by meta-analyses, the more recent reports lacked the provision of definitive response in terms of hard clinical endpoints. Regrettably, pivotal trials designed to conclusively determine the efficacy of cell-based therapeutics in such a challenging clinical condition are therefore still missing. Considering this, a comprehensive reappraisal of cardiac cell-based therapy role in RA seems warranted and timely, since a number of crucial cell- and patient-related aspects need to be systematically analysed. As an example, the large variability in efficacy endpoint selection appears to be a limiting factor for the advancement of cardiac cell-based therapy in the field. This review will provide an overview of the key elements that may have influenced the results of cell-based trials in the context of RA, focusing in particular on the understanding at which the extent of angina-related endpoints may predict cell-based therapeutic efficacy
Estimation of Aortic Stiffness with BramwellâHill Equation: A Comparative Analysis with CarotidâFemoral Pulse Wave Velocity
Aortic stiffness is an important clinical parameter for predicting cardiovascular events. Carotidâfemoral pulse wave velocity (cf-PWV) has been proposed for performing this evaluation non-invasively; however, it requires dedicated equipment and experienced operators. We explored the possibility of measuring aortic stiffness using ultrasound scans of the abdominal aorta coupled with the BramwellâHill equation. Healthy subjects were investigated; measurements of cf-PWV were taken by arterial tonometry and aortic systo-diastolic pressure difference was estimated using a validated model. Pulsatility of an abdominal tract of aorta was assessed by automated processing of ultrasound scans. Through a BlandâAltmann analysis, we found large biases when estimating each parameter by applying the BramwellâHill equation to the measured values of the other two paramters (bias, ± 1.96 SD; PWV, about 2.1 ± 2.5 m/s; pulsatility, 12 ± 14%; pressure jump, 47 ± 55 mmHg). These results indicate that the two measures are not interchangeable, and that a large part of the bias is attributable to blood pressure estimation. Further studies are needed to identify the possible sources of bias between cf-PWV and aortic pulsatility
Antiplatelet theRapy after Genous EPC-capturing coroNary stenT implantatiOn: The ARGENTO Study: A prospective, multicenter registry
Background: To investigate the safety and efficacy of Genous Bio-engineered R stent (GRS) with †15-day or > 15-day dual antiplatelet therapy (DAT), in patients undergoing percutaneous coronary intervention (PCI), with known or expected low compliance to long-term DAT (Antiplatelet theRapy after Genous EPC-capturing coroNary stenT implantatiOn - ARGENTO Study). Methods: Consecutive patients without †12-month revascularization history, known statins allergy, known hypersensitivity reaction or previous or concomitant monoclonal and/or recombinant antibodies therapy, treated with single- or multivessel PCI plus GRS, were prospectively enrolled, at four PCI centers. Major adverse cardiac events (MACEs), the composite of cardiac death, any myocardial infarction (MI) and target vessel revascularization (TVR), and stent thrombosis (ST) cumulative incidences were evaluated. Results: Between March 2008 and March 2010, 384 patients (70.3% male, 423 lesions) were enrolled. At follow-up (22.8 ± 13.6 months), 8.6% MACEs, 3.4% cardiac death, 3.4% any MI, 4.7% TVR and 2.3% overall ST (definite/probable ST 1.3%) rates were reported, without differences between †15-day and > 15-day DAT groups. At Cox multivariable-adjusted regression analysis (Hosmer-Lemeshow statistic, p = 0.50) female sex, diabetes, previous PCI history, 15 days). © 2012 Elsevier Ireland Ltd